TrialThe Journal of clinical investigation2026
Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.
Pasquale Mone et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.